Results 251 to 260 of about 24,787 (310)

Patterns and Clinical Efficacy of Biologics Switching in Patients With Severe Asthma: A Systematic Review and Meta‐Analysis

Allergy, Volume 81, Issue 5, Page 1548-1570, May 2026.
This meta‐analysis included 2292 patients with severe asthma who underwent biologic switching across 23 countries/regions. The most prevalent switching pattern was from mepolizumab to benralizumab, with suboptimal asthma control being the primary reason.
Yang Zheng, Ya‐chun Li, Sheng‐jie Li, Meng Xu, Jia‐qian Hu, Wen‐qu Tian, Shi‐wei Chen, Xue‐hui Li, Ying He, Gan Lu, Mübeccel Akdis, Ioana Agache, Cezmi A. Akdis, Ya‐dong Gao   +13 more
wiley   +1 more source

Nail dystrophy successfully treated with dupilumab in pediatric atopic dermatitis: case series and literature review. [PDF]

Front Immunol
Wang Q, Liu J, Yang G, Liu W, Zhou X, Zhang L.   +5 more
europepmc   +1 more source

Mixed Signals: T Cells as Architects of IgE Immunity

Immunological Reviews, Volume 339, Issue 1, May 2026.
ABSTRACT Food allergen‐specific IgE can cause significant pathology, yet the pathways that generate pathogenic, high‐affinity IgE remain incompletely understood. Increasing evidence suggests that IgE responses arise from the integration of multiple, and sometimes opposing, T cell–derived cues.
Abigail L. Tierney, Wallace P. Bezerra, Stephanie C. Eisenbarth, Adam Williams   +3 more
wiley   +1 more source

Authors' Response to Comment on published article "A Real-World Study of Tofacitinib in Indian Patients with Refractory Moderate-to-Severe Atopic Dermatitis, its Economic Considerations and Immunological Rationale". [PDF]

Indian Dermatol Online J
Sardana K, Sharath S, Meena SK, Khurana A, Dhir B.   +4 more
europepmc   +1 more source

Safety and efficacy of nemolizumab for atopic dermatitis up to 2 years in open‐label extension study

Journal of the European Academy of Dermatology and Venereology, Volume 40, Issue 5, Page 841-855, May 2026.
This study evaluated long‐term safety and efficacy in patients with moderate‐to‐severe atopic dermatitis. Patients with and without previous nemolizumab experience received nemolizumab 30 mg Q4W plus TCS/TCI. Nemolizumab was well‐tolerated through 104 weeks with clinically meaningful improvements in disease signs and symptoms.
Matthias Augustin, Marie Tauber, Robert Sidbury, Jonathan I. Silverberg, Kim A. Papp, Diamant Thaçi, Marjolein S. De Bruin‐Weller, Adam Reich, Ketty Peris, Kirk Barber, Ryszard Galus, Andrzej Kaszuba, Matthew Zirwas, Walter K. Nahm, Gretel Trullenque, Laura Maintz, Sady Alpizar, Sang Wook Son, Vivian Laquer, Linda Stein Gold, Soo Yeon Cheong, Anna Ryzhkova, Agnes Drahos, Liliana Ulianov, Christophe Piketty   +24 more
wiley   +1 more source

Advance in biologics for chronic rhinosinusitis with nasal polyps. [PDF]

Front Allergy
Di Y, Zeng R, Huang L, Wu Y, Wu Q.
europepmc   +1 more source

Addition of dupilumab for patients with aspirin-exacerbated respiratory disease who have poor response to aspirin therapy after desensitization

Pooja M. Achanta, Joel Swirnoff, Rachel E Parigian, Tanya M. Laidlaw, Kathleen M. Buchheit   +4 more
openalex   +2 more sources

Matching-Adjusted Indirect Comparison of the Efficacy of Delgocitinib Cream and Dupilumab in the Treatment of Moderate to Severe Atopic Hand Eczema [PDF]

David Cohen, Anthony Bewley, Andreas Wollenberg, Chih-ho Hong, April W. Armstrong, Emilie Jonsen, Douglas Maslin, Henrik Thoning, Rie von Eyben, Raj Chovatiya   +9 more
openalex   +1 more source

50699 Pembrolizumab-Induced Lichenoid Drug Eruption Successfully Treated with Dupilumab – A Case Report [PDF]

Jason Eakes, Leigh Hatch, Kerry Hennessy, Sairekha Ravichandran, Noura Ayoubi, Kayla Fourzali, Julie Z. Yi, Amanda Krenitsky, Alison H. Kucharik, Lilia Correa‐Selm   +9 more
openalex   +1 more source

Rapid improvement of itch with nemolizumab in atopic dermatitis and prurigo nodularis phase 3 studies

Journal of the European Academy of Dermatology and Venereology, Volume 40, Issue 5, Page 867-875, May 2026.
Achieving rapid control of itch in atopic dermatitis and prurigo nodularis may minimize symptomatology and disease burden. Analysis of clinical trials in atopic dermatitis and prurigo nodularis showed significantly more patients in nemolizumab versus placebo groups achieved a meaningful clinical response in itch within 48 h, and separation increased ...
Sonja Ständer, Sarina B. Elmariah, Shawn G. Kwatra, Gil Yosipovitch, Andrew E. Pink, Soo Yeon Cheong, Xiaoxiao Chen, Zarif K. Jabbar‐Lopez, Liliana Ulianov, Christophe Piketty, Jonathan I. Silverberg   +10 more
wiley   +1 more source